A Phase 2 study evaluating NBI-'568 in bipolar mania
Latest Information Update: 20 Jan 2025
At a glance
- Drugs HTL-0016878 (Primary)
- Indications Bipolar depression
- Focus Adverse reactions
Most Recent Events
- 20 Jan 2025 New trial record
- 14 Jan 2025 According to a Nxera Pharma media release, company expected to initiate this study in 2H 2025.